Shire Human Genetic Therapies, Inc. is 10% Owner at Translate Bio, Inc. (TBIO). They have made 1 open-market trade across 1 company since 2020, most recently 2020-06-02.
CIK 0001745009
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| TBIO | 6,865,078 | $22.2M |
Shares reported on the most recent Form 4, priced at the 2020-06-03 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TBIO | SELL | 2020-06-01 | 2020-06-03 | $19.81 | $8.4M | -0.1% | -7.5% | -7.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.